Biogen slashes price of Alzheimer’s drug Aduhelm, as it faces obstacles
The New York Times: Peter Whitehouse, professor of neurology, was part of a group of experts who called on a new Alzheimer’s medication to be revoked by the FDA, noting the scientific evidence showed the drug did not provide a clear benefit to patients and that it carried risks of dangerous side effects.
